FrancophonIA/ELRC3.0 huggingface dataset:
English: Immunocompromised individuals (see section 4.3) Necrotizing retinitis has been reported post-marketing in immunocompromised individuals.
Slovenian: Pri posameznikih z oslabljenim imunskim sistemom so v obdobju trženja zdravila poročali o nekrotizirajočem retinitisu.
English: 2 Wistar RA 27/3 strain (live, attenuated)...............not less than 3.00 log10 CCID Varicella virus
Slovenian: Virus rdečk 2, sev Wistar RA 27/3 (živ, oslabljen) ..............................najmanj 3,00 log10 CCID
English: EU/1/05/323/001 - pack of 1 EU/1/05/323/002 - pack of 10
Slovenian: EU/1/05/323/001 - pakiranje po 1 EU/1/05/323/002 - pakiranje po 10
English: Therefore, caution should be exercised when considering whether to administer ProQuad to a breast-feeding woman.
Slovenian: Zato je pri odločitvi o cepljenju doječe matere s cepivom ProQuad potrebna previdnost.
English: Injection site complaints (Burning and/or Stinging of short duration, Eczema, Oedema/Swelling, Hive-like rash, Hematoma, Induration, Lump, Vesicles, Wheal and Flare), Inflammation, Lip abnormality, Papillitis, Roughness/Dryness, Stiffness, Trauma, Varicella-like rash, Venipuncture site haemorrhage, Warm sensation, Warm to touch
Slovenian: ‡, eritem ‡ ali bolečina/občutljivost/bolečnost na mestu injiciranja zelo pogosti ekhimoza ali oteklina ‡ na mestu injiciranja, izpuščaj na mestu injiciranja pogosti astenija/utrujenost, krvavitev na mestu injiciranja, zatrdlina ali toplota na mestu injiciranja, oteklina na mestu injiciranja, slabo počutje občasni gripi podobna bolezen, luščenje kože na mestu injiciranja, sprememba barve na mestu injiciranja, srbečica na mestu injiciranja, nespecifični izpuščaj na mestu injiciranja, reakcija na mestu injiciranja, brazgotina na mestu injiciranja, hipertermija, bolečina redki reakcije na mestu injiciranja (kratkotrajen pekoč občutek in/ali zbadanje, ekcem, edem/oteklina, koprivnici podoben izpuščaj, hematom, zatrdlina, bula, mehurčki, mehurčki in rdečina - kot pri alergijskih kožnih testih, vnetje, nenormalnost ustnice, papilitis, hrapava/suha koža, otrdelost, poškodba, noricam podoben izpuščaj, krvavitev na mestu punkcije vene, občutek toplote, toplota na dotik neznana pogostnost
English: Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent patients; therefore, some of these patients may acquire measles, mumps, rubella, or varicella in case of contact, despite appropriate vaccine administration.
Slovenian: Pri bolnikih z oslabljenim imunskim sistemom, ki nimajo kontraindikacij za cepljenje s tem cepivom (glejte poglavje 4.3), odziv morda ne bo tako dober kot pri bolnikih z normalnim imunskim odzivom.
English: ProQuad Powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live)
Slovenian: ProQuad prašek in vehikel za suspenzijo za injiciranje v napolnjeni injekcijski brizgi cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
English: How to store ProQuad
Slovenian: Shranjevanje cepiva ProQuad
English: ProQuad Powder and solvent for suspension for injection Measles, mumps, rubella and varicella vaccine (live)
Slovenian: ProQuad prašek in vehikel za suspenzijo za injiciranje cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
English: 2 Wistar RA 27/3 strain (live, attenuated)...............not less than 3.00 log10 CCID50* Varicella virus
Slovenian: Virus rdečk 2, sev Wistar RA 27/3 (živ, oslabljen)................................najmanj 3,00 log10 CCID50*
English: Bronchial spasm, Bronchitis, Epistaxis, Pneumonitis (see section 4.3), Pneumonia, Pulmonary congestion, Rhinitis, Sinusitis, Sore throat
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora kašelj, kongestija nosu, kongestija dihal, izcedek iz nosu občasni astma, pljučna kongestija, bolezni obnosnih votlin, kihanje, piskanje redki bronhialni spazem, bronhitis, epistaksa, pnevmonitis (glejte poglavje 4.3), pljučnica, pljučna kongestija, rinitis, sinusitis, bolečine v grlu neznana pogostnost
English: Withdraw the entire content of the solvent vial into a syringe.
Slovenian: Celotno vsebino viale z vehiklom povlecite v brizgo.
English: ProQuad with Solvent for reconstitution supplied in a Pre-filled syringe: Powder in a vial (glass) with a stopper (butyl rubber) and solvent in a pre-filled syringe (glass) with attached needle with plunger stopper (chlorobutyl rubber) and needle shield (natural rubber) in a pack size of 1 and 10.
Slovenian: Prašek v viali (steklo) z zamaškom (butilna guma) in vehikel v napolnjeni injekcijski brizgi (steklo) s pritrjeno iglo z batnim zamaškom (klorobutilna guma) in z zaščito za iglo iz naravne gume v pakiranjih po 1 in 10.
English: In the event of either being observed, discard the vaccine.
Slovenian: Če opazite prisotnost tujih delcev in/ali nenavaden izgled cepiva, je treba cepivo zavreči.
English: However, post-exposure prophylaxis for varicella and measles has been demonstrated with Varicella Vaccine live (Oka/Merck) and the measles-containing vaccines manufactured by Merck & Co., Inc., respectively.
Slovenian: Dokazana pa je bila profilaksa s cepivom z živim virusom noric (Oka/Merck) po izpostavitvi noricam ter profilaksa s cepivi, ki vsebujejo cepivo proti ošpicam izdelovalca Merck & Co., Inc., po izpostavitvi ošpicam.
English: ProQuad - Powder in vial and solvent in pre-filled syringe with 1 unattached needle - Pack of 1,
Slovenian: ProQuad - prašek v viali in vehikel v napolnjeni injekcijski brizgi brez igle - pakiranje po 1, 10,
English: Conjunctivitis, Eye discharge, Eyelid inflammation, Eye irritation, Eye swelling, Ocular hyperaemia, Tearing, Visual discomfort
Slovenian: Očesne bolezni konjunktivitis, izcedek iz oči, vnetje očesne veke, draženje oči, otekanje oči, hiperemija zrkla, solzenje, neprijeten občutek v očeh redki edem vek, draženje, optični nevritis, retinitis, retrobulbarni nevritis neznana pogostnost
English: ProQuad powder and solvent for suspension for injection in a pre-filled syringe Measles, mumps, rubella and varicella vaccine (live)
Slovenian: ProQuad prašek in vehikel za suspenzijo za injiciranje ProQuad prašek in vehikel za suspenzijo za injiciranje v napolnjeni injekcijski brizgi cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo)
English: Abdominal pain upper, Abnormal faeces, Constipation, Flatulence, Nausea, Salivation increase, Stomatitis, Teething
Slovenian: Bolezni prebavil driska, bruhanje pogosti bolečine v zgornjem delu trebuha, nenormalno blato, zaprtje, vetrovi, navzea, povečano slinjenje, stomatitis, dobivanje zob redki bolečine v trebuhu, hemohezija, razjeda v ustih neznana pogostnost
English: ProQuad should not be given to pregnant women.
Slovenian: Nosečnic se ne sme cepiti s cepivom ProQuad.
English: Merck Sharp & Dohme BV Waarderweg 39, 2031 BN Haarlem P.O.
Slovenian: Merck Sharp & Dohme BV Waarderweg 39
English: Extravasation
Slovenian: Odmerjanje
English: Information was available from 23 patients.
Slovenian: Na voljo so bile informacije o 23 bolnikih.
English: London, 19 March 2008 Doc.
Slovenian: London, 19. marca 2008 Sklic na dok.
English: International non-proprietary name (INN): miglustat
Slovenian: Mednarodno nelastniško ime (INN): miglustat
English: Ref. EMEA/121008/2008
Slovenian: EMEA/186568/2008
English: The medicine was also studied in 12 patients aged less than 12 years.
Slovenian: Zdravilo so preučevali tudi pri 12 bolnikih, starih manj kot 12 let.
English: The disease can result in dementia and is usually fatal before the patient has reached adulthood.
Slovenian: Bolezen lahko privede do demence in je običajno usodna, še preden bolnik doseže obdobje odraslosti.
English: This is expected to reduce the symptoms of the disease.
Slovenian: To bi naj izboljšalo simptome bolezni.
English: The company had requested a re-examination of the negative opinion, but this had not yet finished when the company withdrew.
Slovenian: Družba je zahtevala ponovno presojo negativnega mnenja, ki pa še ni bila zaključena, ko je družba umaknila vlogo.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for ZAVESCA
Slovenian: VPRAŠANJA IN ODGOVORI V ZVEZI Z UMIKOM VLOGE ZA SPREMEMBO DOVOLJENJA ZA PROMET z zdravilom ZAVESCA
English: There are no consequences on the use of Zavesca in its authorised indication, for which the balance of benefits and risks remains unchanged.
Slovenian: Umik nima nobenih posledic za uporabo zdravila Zavesca za odobreno indikacijo, pri kateri ostaja razmerje med koristmi in tveganji nespremenjeno.
English: The effects of Zavesca were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Zavesca so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
English: Symptoms include a progressive loss of co-ordination, problems with ‘saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, increased muscle tone, fits, and learning difficulties.
Slovenian: Njeni simptomi vključujejo progresivno izgubljanje koordinacije, težave s hitrimi, sunkovitimi gibi oči, ki lahko privedejo do okrnjenega vida, zaostanek v razvoju, težave pri požiranju, povečan mišični tonus, krči ter težave pri učenju.
English: In patients with this disease, fatty substances such as ‘glycosphingolipids' build up within cells in the brain, as well as elsewhere in the body.
Slovenian: Pri bolnikih s to boleznijo se maščobne snovi, kot npr. „glikosfingolipidi“, kopičijo v celicah v možganih, kakor tudi drugje po telesu.
English: What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Zavesca?
Slovenian: Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Zavesca?
English: The medicine showed a very limited benefit in the main study: there was only a marginal difference in the change in the speed of eye movements between the patients taking Zavesca and those receiving standard care, and there were uncertainties over whether looking at eye movements was the best way to measure the medicine's effectiveness.
Slovenian: Zdravilo je v glavni študiji izkazalo zelo omejeno korist: pri spremembi hitrosti gibov z očmi so ugotovili le minimalno razliko med bolniki, ki so prejemali zdravilo Zavesca, in tistimi, ki so prejemali standardno oskrbo, poleg tega ni bilo gotovo, ali je preučevanje gibov oči najboljši način za merjenje učinkovitosti zdravila.
English: The company also presented additional information from a worldwide survey of patients with Niemann Pick type C disease who had been treated with miglustat outside of the main study.
Slovenian: Družba je predstavila tudi dodatne informacije iz globalne raziskave bolnikov z Niemann-Pick-ovo boleznijo tipa C, ki so bili zdravljeni z miglustatom izven glavne študije.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Zavesca.
Slovenian: Družba je obvestila CHMP, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Zavesca.
English: By preventing the enzyme from working, miglustat can reduce the production of glycosphingolipids in cells.
Slovenian: S tem, ko preprečuje delovanje encima, lahko miglustat zmanjša delež glikosfingolipidov v celicah.
English: In patients with this disease, a fatty substance called glucosylceramide builds up in different parts of the body, such as the spleen, liver, and bones.
Slovenian: Pri bolnikih s to boleznijo se maščoba, imenovana glukozilceramid, kopiči v različnih delih telesa, kot so vranica, jetra in kosti.
English: On 19 February 2008, Actelion Registration Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Zavesca, in the treatment of neurological manifestations in patients with Niemann Pick type C disease.
Slovenian: Družba Actelion Registration Ltd. je dne 19. januarja 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo za zdravilo Zavesca, in sicer zdravljenje nevroloških manifestacij pri bolnikih z Niemann-Pick-ovo boleznijo tipa C.
English: Zavesca is a hard white capsule, which contains the active substance miglustat.
Slovenian: Zdravilo Zavesca so trde bele kapsule, vsebujoče učinkovino miglustat.
English: Gaucher disease is a rare, inherited disease that affects the way the body handles fats.
Slovenian: Gaucherjeva bolezen je redka dedna bolezen, ki vpliva na način, kako telo presnavlja maščobe.
English: Niemann Pick type C disease is a rare inherited disease that affects the way the body handles fats.
Slovenian: Niemann-Pick-ova bolezen tipa C je redka dedna bolezen, ki vpliva na način, kako telo presnavlja maščobe.
English: Miglustat, the active substance in Zavesca, prevents an enzyme called ‘glucosylceramide synthase' from working.
Slovenian: Miglustat, učinkovina zdravila Zavesca, preprečuje delovanje encima, imenovanega „glukozilceramid sintaza“.
English: Zavesca was also linked to side effects affecting the stomach and gut, as well as cases of weight loss and thrombocytopenia (low blood platelet counts).
Slovenian: Zdravilo Zavesca je bilo tudi povezano z neželenimi učinki za želodec in črevesje, kakor tudi s primeri izgube telesne mase in trombocitopenije (nizke ravni krvnih ploščic).
English: In the new indication, Zavesca was expected to be used to treat the ‘neurological' symptoms of Niemann Pick type C disease (affecting the brain and nervous system).
Slovenian: Pri novi indikaciji bi se naj zdravilo Zavesca uporabljalo za zdravljenje nevroloških simptomov Niemann-Pick-ove bolezni tipa C (ki prizadene možgane in živčevje).
English: Based on the review of the data and the company's response to the CHMP's list of questions, at the time of the withdrawal, the CHMP had given a negative opinion and did not recommend the approval of Zavesca for the treatment of neurological manifestations in patients with Niemann Pick type C disease.
Slovenian: Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je do umika vloge zastavil CHMP, je ta izrazil negativno mnenje in ni priporočil odobritve zdravila Zavesca za zdravljenje nevroloških manifestacij pri bolnikih z Niemann-Pick-ovo boleznijo tipa C.
English: What was Zavesca expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Zavesca uporabljalo?
English: The CHMP acknowledged that there are no alternative treatments for Niemann Pick type C disease, but it was concerned that a benefit of Zavesca in the treatment of the neurological symptoms of Niemann Pick type C disease had not been sufficiently demonstrated.
Slovenian: CHMP se je strinjal, da za Niemann-Pick-ovo bolezen tipa C ni alternativnega zdravljenja, vendar pa je izrazil pomislek, da korist zdravila Zavesca pri zdravljenju nevroloških simptomov Niemann-Pickove bolezni tipa C ni bila zadostno dokazana.
English: What is happening for Zavesca for the treatment of type 1 Gaucher disease?
Slovenian: Kakšne so posledice za zdravilo Zavesca, indicirano za zdravljenje Gaucherjeve bolezni tipa 1?
English: Zavesca was designated as an orphan medicinal product on 16 February 2006 for Niemann Pick type C disease.
Slovenian: Zdravilo Zavesca je bilo dne 16. februarja 2000 določeno kot zdravilo sirota za zdravljenje NiemannPick-ove bolezni tipa C.
English: It is used for the treatment of mild to moderate type 1 Gaucher disease.
Slovenian: Zdravilo Zavesca je namenjeno za zdravljenje blage do zmerne oblike Gaucherjeve bolezni tipa 1.
English: The study compared the effects of adding Zavesca taken at a dose of 200 mg three times a day to standard care with the effects of standard care alone.
Slovenian: Učinkovitost zdravila Zavesca so preučevali v eni glavni študiji, ki je vključevala 29 bolnikov v starosti 12 let in več z Niemann-Pick-ovo boleznijo tipa C. V okviru študije so primerjali učinek dodajanja zdravila Zavesca v odmerku 200 mg trikrat dnevno k standardnemu zdravljenju z učinkom standardnega zdravljenja samega.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Zavesca in the treatment of neurological manifestations in Niemann Pick type C disease did not outweigh its risks.
Slovenian: CHMP je tedaj menil, da koristi zdravila Zavesca pri zdravljenju nevroloških simptomov NiemannPick-ove bolezni tipa C ne odtehtajo z njim povezanih tveganj.
English: How is Zavesca expected to work?
Slovenian: Kako bi naj zdravilo Zavesca delovalo?
English: was the change in the speed at which the patients made saccadic horizontal eye movements after a year's treatment.
Slovenian: Glavno merilo učinkovitosti je bila sprememba hitrosti, s katero je bolnik delal sunkovite vodoravne gibe z očmi.
English: ‘Complicated' means that the infection is difficult to treat.
Slovenian: „Zapletena“ pomeni, da je okužbo težko zdraviti.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tygacil on 24 April 2006.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Tygacil, veljavno po vsej Evropski uniji, izdala 24. aprila 2006.
English: Treatment lasts from 5 to 14 days.
Slovenian: Zdravljenje traja od pet do 14 dni.
English: The full EPAR for Tygacil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tygacil je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Tygacil?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tygacil?
English: Each infusion should last between 30 and 60 minutes.
Slovenian: Posamezna infuzija naj traja od 30 do 60 minut.
English: What benefit has Tygacil shown during the studies?
Slovenian: Kakšne koristi je zdravilo Tygacil izkazalo med študijami?
English: Tygacil tigecycline
Slovenian: Tygacil tigeciklin
English: By blocking the production of new proteins, the bacteria cannot multiply and they eventually die.
Slovenian: Z zaviranjem tvorbe novih beljakovin se bakterije ne morejo več razmnoževati in sčasoma odmrejo.
English: The length of treatment depends on where the infection is, how severe it is, and the patient's response to treatment.
Slovenian: Trajanje zdravljenja je odvisno od mesta okužbe, resnosti okužbe ter od bolnikovega odziva na zdravljenje.
English: In all of the studies, the main measure of effectiveness was the number of patients whose infection was cured.
Slovenian: Glavno merilo učinkovitosti v vseh teh študijah je bilo število bolnikov, pri katerih se je okužba pozdravila.
English: The CHMP decided that Tygacil's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Tygacil večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: It is also used to treat complicated infections in the abdomen.
Slovenian: Uporablja se tudi za zdravljenje zapletenih trebušnih okužb.
English: This document is a summary of the European Public Assessment Report (EPAR) for Tygacil.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tygacil.
English: Patients allergic to tetracycline antibiotics may also be allergic to Tygacil.
Slovenian: Bolniki, ki so alergični na tetraciklinske antibiotike, utegnejo biti alergični tudi na zdravilo Tygacil.
English: Before using Tygacil, doctors should consider official guidance on the appropriate use of antibiotics.
Slovenian: Preden zdravnik predpiše zdravilo Tygacil, mora upoštevati uradne smernice za ustrezno uporabo antibiotikov.
English: For more information about treatment with Tygacil, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Tygacil preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: A risk management plan has been developed to ensure that Tygacil is used as safely and effectively as possible.
Slovenian: Za zagotovitev čim varnejše in učinkovitejše uporabe zdravila Tygacil je bil pripravljen načrt obvladovanja tveganj.
English: It works by blocking the bacteria's ribosomes, the parts of the cell where new proteins are made.
Slovenian: Deluje tako, da zavira ribosome bakterij oziroma tiste dele celic, ki proizvajajo nove beljakovine.
English: Tygacil should be used only when other antibiotics are not suitable.
Slovenian: Zdravilo Tygacil se lahko uporablja samo, kadar zdravljenje z drugimi antibiotiki ni primerno.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: What is the risk associated with Tygacil?
Slovenian: Kakšna tveganja so povezana z zdravilom Tygacil?
English: Tygacil has been compared with other antibiotics in four main studies.
Slovenian: Zdravilo Tygacil so z drugimi antibiotiki primerjali v štirih glavnih študijah.
English: Other information about Tygacil:
Slovenian: Druge informacije o zdravilu Tygacil:
English: The list of bacteria against which Tygacil is active can be found in the summary of product characteristics (also part of the EPAR).
Slovenian: Seznam bakterij, proti katerim zdravilo Tygacil učinkuje, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako sestavni del EPAR).
English: Although there are few data in children, studies suggest that Tygacil can be a treatment alternative for complicated skin and soft tissue or abdominal infections, with bacteria resistant to other antibiotics.
Slovenian: Čeprav je za zdravljenje otrok na voljo le malo podatkov, študije kažejo, da je zdravilo Tygacil lahko alternativno zdravilo za zapletene okužbe kože in mehkih tkiv ali okužbe trebušne votline, kadar so bakterije odporne proti drugim antibiotikom.
English: Tygacil must not be used in people who are hypersensitive (allergic) to tigecycline or any of the other ingredients.
Slovenian: Zdravila Tygacil ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) tigeciklin ali katero koli drugo sestavino zdravila.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tygacil, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Why has Tygacil been approved?
Slovenian: Zakaj je bilo zdravilo Tygacil odobreno?
English: In the four main studies, Tygacil was as effective as the comparator antibiotics.
Slovenian: V štirih glavnih študijah je bilo zdravilo Tygacil enako učinkovito kot primerjalni antibiotiki.
English: Tygacil is used to treat adults and children older than eight years with complicated infections of the skin and soft tissue (the tissue below the skin), but not foot infections in people with diabetes.
Slovenian: Zdravilo Tygacil se uporablja za zdravljenje odraslih in otrok, starejših od osem let, z zapletenimi okužbami kože in mehkih (podkožnih) tkiv, vendar ne za zdravljenje okužb stopal pri bolnikih s sladkorno boleznijo.
English: The active substance in Tygacil, tigecycline, belongs to a group of antibiotics called ‘glycylcyclines'.
Slovenian: Zdravilna učinkovina zdravila Tygacil, tigeciklin, spada v skupino antibiotikov, imenovanih „glicilciklini“.